MedTrace Logo

Study of ZV0203 in Patients With HER2-Positive Advanced Solid Tumors

NCT05423977 · Status: ENROLLING_BY_INVITATION · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-09-30

No results posted yet for this study

Summary

An open-label, multicenter, phase I dose-escalation study to assess the safety, Pharmacokinetic (PK), immunogenicity and preliminary anti-tumor activity of ZV0203 in patients with HER2-Positive advanced solid tumors

Conditions

  • HER2-positive Advanced Solid Tumor

Interventions

DRUG

ZV0203

Participants will be allocated to one of the following dose groups: 0.3, 0.6, 1.2, 1.8, 2.7 and 3.6 mg/kg, and receive a treatment of ZV0203-ADC followed by 21 days of dose limited toxicity (DLT) observation period.

Sponsors & Collaborators

  • Hangzhou Adcoris Biopharmacy Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Jie Hou, MD,PhD · Peking University Care Luzhong Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-17
Primary Completion
2023-05-05
Completion
2026-07-07

Countries

  • China

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05423977 on ClinicalTrials.gov